<DOC>
	<DOC>NCT00215709</DOC>
	<brief_summary>This pilot study is designed to determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in older men with hormone refractory prostate cancer.</brief_summary>
	<brief_title>Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>The information obtained from this trial will help determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in this patient population. If the data from this phase I trial are encouraging, a phase II trial will be conducted to further assess the efficacy of this dosing schedule.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>age ≥ 65 years; histologically confirmed adenocarcinoma of the prostate; metastatic disease; unresponsive or refractory to hormonal therapy, as defined by at least 1 of the following criteria: progression of bidimensionally measurable disease; progression of evaluable but not measurable disease (bone scan); at least 2 consecutive rises in PSA at least 1 week apart; patients must have serum testosterone levels &lt; 50 ng/mL at time of study entry. For patients who are medically castrated, lutenizing hormone releasing hormone analog must continue to maintain testicular suppression; prior nonsteroidal antiandrogens (flutamide, ketoconazole, bicalutamide, or nilutamide) allowed if disease progression occurred. No evidence of response after antiandrogen withdrawal within 4 weeks for patients treated with flutamide, ketoconazole, nilutamide and 6 weeks for patients treated with bicalutamide; chemotherapy naïve; full recovery from the effects of any prior surgery or radiation therapy. At least 4 weeks since any radiation therapy; ECOG performance status 02; adequate kidney, liver, and bone marrow functions; signed studyspecific informed consent form. Concurrent chemotherapy or immunotherapy; Patients who have received an investigational drug within 4 weeks of registration; Prior or concurrent malignancies (other than surgically treated carcinoma in situ of the cervix and squamous or basal cell carcinoma of the skin) within the preceding five years; Serious medical or psychiatric illness which would prevent informed consent; Life expectancy &lt; 3 months; Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled; Known hypersensitivity to study drug or to other drugs formulated with polysorbate 80.</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>elderly</keyword>
</DOC>